|
**Overview**: Hypogonadism Male Panel**Introduction**: The Hypogonadism Male Panel is a diagnostic tool designed to assess male hypogonadism using serum samples. In India, male hypogonadism (primary/secondary) affects ~10-20 percent of infertile men and aging males, presenting with low libido, erectile dysfunction, fatigue, infertility, and osteoporosis. High morbidity from under-testing in rural/low-SES men with infertility or andropause symptoms, limited endocrine labs, delayed testosterone replacement leading to reduced quality of life or bone loss. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs immunoassay for testosterone, LH, and FSH over 1-2 days with high accuracy, valuable for differentiating primary (high LH/FSH) from secondary (low/normal) hypogonadism. This diagnostic falls under hormonal screening and targets men with symptoms or infertility, addressing accurate detection to guide testosterone therapy or gonadotropin treatment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise hormonal assessment and improving reproductive/male health. Its serum-based approach ensures reliable measurement.**Other Names**: Hypogonadism Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Male hypogonadism panel standard; in India, used in andrology clinics.**Purpose**: The test assesses 3 parameters including testosterone to guide hypogonadism evaluation, differentiate primary/secondary, inform therapy.**Test Parameters**: 1. Testosterone, 2. LH, 3. FSH.**Pretest Condition**: Fasting 10-12 hours recommended (morning sample ideal); patients should report low libido or infertility.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on erectile dysfunction, infertility, puberty delay.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hypogonadism including osteoporosis, benefits of diagnosis, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or diurnal variation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low testosterone + high LH/FSH indicates primary; low/normal LH/FSH secondary, necessitating specialist input.**Specialist Consultation**: Endocrinologists or andrologists should be consulted for management.**Additional Supporting Tests**: Semen analysis, testicular ultrasound for confirmation.**Test Limitations**: Morning sample critical; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Andrology Studies India 2023. |
